Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis.

Abstract:

BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical records retrospectively to evaluate the prevalence, risk factors and prognosis of lung cancer in IPF patients. RESULTS:Among all patients with IPF, 114 cases (6.8%) had lung cancer with IPF. The incidence of lung cancer in patients with IPF was 1.03 persons per 100 person-year (25 patients/2408 years). Most cases of lung cancer (73/114, 68.9%) were located in IPF-associated areas; the lung cancer typically developed in peripheral and lower lobe areas. The study revealed that forced vital capacity (% predicted) at the initial diagnosis and development of lung cancer were independent prognostic factors in patients with IPF. CONCLUSIONS:Lung cancer in patients with IPF was significantly related with the IPF prognosis. An active evaluation should be performed in patients with IPF to detect lung cancer early.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Lee KJ,Chung MP,Kim YW,Lee JH,Kim KS,Ryu JS,Lee HL,Park SW,Park CS,Uh ST,Lee YC,Park SJ,Kim KH,Jeon YJ,Choi WI,Park YB,Kim DS,Jeong SH,Lee JH,Park MS

doi

10.1111/j.1759-7714.2011.00107.x

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

150-155

issue

2

eissn

1759-7706

issn

1759-7714

journal_volume

3

pub_type

杂志文章
  • Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.

    abstract:BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13008

    authors: Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

    更新日期:2019-04-01 00:00:00

  • Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.

    abstract:BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13370

    authors: Zhang L,Bai L,Liu X,Liu Y,Li S,Liu J,Zhang S,Yang C,Ren X,Cheng Y

    更新日期:2020-05-01 00:00:00

  • Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets.

    abstract:BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13053

    authors: Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

    更新日期:2019-05-01 00:00:00

  • Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature.

    abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00086.x

    authors: Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

    更新日期:2012-02-01 00:00:00

  • The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

    abstract:BACKGROUND:  To evaluate the conditions of palliative chemotherapy in terminally ill patients with advanced non-small cell lung cancer (NSCLC), and to discuss the potential factors that affect the prognosis of these patients. METHODS:  All 205 terminally ill patients with advanced NSCLC, who died in our hospital durin...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00148.x

    authors: Yang D,Qiu M,Zou LQ,Zhang W,Jiang Y,Zhang DY,Yan X

    更新日期:2013-05-01 00:00:00

  • Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

    abstract::After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12416

    authors: Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

    更新日期:2017-07-01 00:00:00

  • LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.

    abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13256

    authors: Li X,Zheng H

    更新日期:2020-02-01 00:00:00

  • Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

    abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13143

    authors: Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

    更新日期:2019-09-01 00:00:00

  • Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.

    abstract::Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13471

    authors: Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

    更新日期:2020-07-01 00:00:00

  • Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

    abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13215

    authors: Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

    更新日期:2019-12-01 00:00:00

  • Salvage surgery using simultaneous clamshell thoracotomy with median sternotomy for mediastinal growing teratoma syndrome.

    abstract::This report describes the case of a 17-year-old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly-growing mediastinal tumor was completely resected in conjunction with right...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13297

    authors: Kao CN,Chou SH,Huang CL,Lin CH,Chiang HH,Lee JY,Li HP,Chang PC,Liu YW

    更新日期:2020-03-01 00:00:00

  • Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.

    abstract:BACKGROUND:Next-generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy; however, little is known about the performance of the Oncomine Dx Target Test compared with conventional single gene tests for detecting EGFR mutations. The objective of this st...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13767

    authors: Sakaguchi T,Iketani A,Furuhashi K,Nakamura Y,Suzuki Y,Ito K,Fujiwara K,Nishii Y,Katsuta K,Taguchi O,Hataji O

    更新日期:2020-12-12 00:00:00

  • Invasive thymoma with intravascular growth into the great veins and right atrium: A case report.

    abstract::Here, we present a case of invasive thymoma with intraluminal growth into the left and right brachiocephalic veins, superior vena cava and the right atrium. Resection of the mass, double partial upper lobe lobectomy and superior vena cava, and left and right brachiocephalic vein replacement were performed. Pathologica...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13242

    authors: Shen W,Cao Y,Wang X,Zhang P,Zhou Q

    更新日期:2020-05-01 00:00:00

  • Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.

    abstract::Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13694

    authors: Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

    更新日期:2020-12-01 00:00:00

  • hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma.

    abstract:BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12761

    authors: Li S,Sun X,Miao S,Lu T,Wang Y,Liu J,Jiao W

    更新日期:2018-08-01 00:00:00

  • MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

    abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13326

    authors: Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

    更新日期:2020-03-01 00:00:00

  • Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12232

    authors: Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

    更新日期:2015-09-01 00:00:00

  • Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding.

    abstract::Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13159

    authors: Tomono H,Soda H,Fukuda Y,Tanaka Y,Ono S,Shimada M,Iwasaki K,Hisanaga M,Yamaguchi H,Mukae H

    更新日期:2019-10-01 00:00:00

  • Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

    abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13163

    authors: Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

    更新日期:2019-10-01 00:00:00

  • The 12th National Lung Cancer Academic Conference in China.

    abstract:BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00125.x

    authors: Liu Y,Chen G,Qiu X,Chen J,Zhou Q

    更新日期:2012-08-01 00:00:00

  • Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker.

    abstract:BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12948

    authors: Zhang YW,Chen QQ,Cao J,Xu LQ,Tang X,Wang J,Zhang J,Dong LX

    更新日期:2019-03-01 00:00:00

  • Uniportal video-assisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center.

    abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13728

    authors: Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

    更新日期:2021-01-06 00:00:00

  • Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

    abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12877

    authors: Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

    更新日期:2018-11-01 00:00:00

  • Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.

    abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13336

    authors: Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

    更新日期:2020-04-01 00:00:00

  • EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

    abstract:BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13253

    authors: Zhang L,Pradhan B,Guo L,Meng F,Zhong D

    更新日期:2020-02-01 00:00:00

  • Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

    abstract:BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13366

    authors: Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

    更新日期:2020-04-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13568

    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.

    abstract:BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13346

    authors: Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

    更新日期:2020-04-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer.

    abstract:BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12500

    authors: Bi MM,Shang B,Wang Z,Chen G

    更新日期:2017-11-01 00:00:00